Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OREX
  • CUSIP: 68616410
Key Metrics:
  • Previous Close: $3.29
  • 50 Day Moving Average: $3.84
  • 200 Day Moving Average: $4.32
  • 52-Week Range: $3.16 - $34.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.72
  • P/E Growth: 0.01
  • Market Cap: $47.99M
  • Outstanding Shares: 14,586,000
  • Beta: 1.98
Profitability:
  • Net Margins: -275.98%
  • Return on Equity: -380.26%
  • Return on Assets: -25.27%
Debt:
  • Debt-to-Equity Ratio: -20.66%
  • Current Ratio: 8.13%
  • Quick Ratio: 7.80%
Additional Links:
Companies Related to Orexigen Therapeutics:

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings
Consensus Rating:Hold (Score: 1.88)
Consensus Price Target: $1.60 (51.37% downside)
Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00View Rating Details
3/16/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$5.00 -> $2.00View Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/29/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00View Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldView Rating Details
12/12/2015Bank of America Corp.Reiterated RatingSellView Rating Details
12/4/2015Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$1.00 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)ViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
Current Year EPS Consensus Estimate: $-7.41 EPS
Next Year EPS Consensus Estimate: $-4.59 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.09)($0.09)($0.09)
Q2 20162($0.14)($0.10)($0.12)
Q3 20162($0.18)($0.10)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Insider Ownership Percentage: 13.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
DateHeadline
investornewswire.com logoCan Shares Of Orexigen Therapeutics, Inc. (NASDAQ:OREX) Hit $5? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - September 27 at 6:31 PM
News IconStock Update: Estimates & Target in Focus for Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Frisco Fastball (NASDAQ:OREX)
friscofastball.com - September 25 at 5:53 PM
News IconLooking Ahead for Orexigen Therapeutics, Inc. (NASDAQ:OREX); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:OREX)
friscofastball.com - September 23 at 6:08 PM
News IconOrexigen Therapeutics Price Target Cut to $11.00 by Analysts at Piper Jaffray (OREX) - Petro Global News 24 (NASDAQ:OREX)
petroglobalnews24.com - September 21 at 10:43 AM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : September 16, 2016 (NASDAQ:OREX)
www.capitalcube.com - September 16 at 6:25 PM
News IconOrexigen Therapeutics Inc. (OREX) Shares Down 2.8% - NewsDen (NASDAQ:OREX)
newsden.net - September 15 at 10:07 AM
News IconAnalysts Take the Wheel on Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:OREX)
friscofastball.com - September 13 at 11:30 AM
investornewswire.com logoCan Shares Of Orexigen Therapeutics, Inc. (NASDAQ:OREX) Hit $5 - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - September 12 at 6:20 PM
News IconAnalysts Place Orexigen Therapeutics, Inc. (NASDAQ:OREX) Under the Lens of the Microscope - Post News (NASDAQ:OREX)
www.kentuckypostnews.com - September 12 at 6:20 PM
finance.yahoo.com logoOrexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:OREX)
finance.yahoo.com - September 7 at 6:45 PM
News IconValeant to distribute Orexigen Therapeutics' Contrave in Canada (NASDAQ:OREX)
www.pharmabiz.com - September 2 at 11:28 AM
News IconOrexigen Therapeutics, Inc. (NASDAQ: OREX) Finds Partner To Share Burden Of Distributing Contrave - Scibility Media (NASDAQ:OREX)
scibilitymedia.com - September 1 at 9:47 AM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : August 31, 2016 (NASDAQ:OREX)
www.capitalcube.com - September 1 at 9:47 AM
reuters.com logoBRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave (NASDAQ:OREX)
www.reuters.com - August 31 at 11:40 AM
streetinsider.com logoOrexigen (OREX) Enters Contrave Commercialization Agreement with Valeant (VRX) Unit (NASDAQ:OREX)
www.streetinsider.com - August 31 at 11:40 AM
thecountrycaller.com logoValeant Pharmaceuticals Intl Inc's (VRX) Agreement with Orexigen Therapeutics Cheers Investors (NASDAQ:OREX)
www.thecountrycaller.com - August 31 at 11:40 AM
News IconOrexigen in Canadian Marketing Pact With Valeant for Diet Drug (NASDAQ:OREX)
ih.advfn.com - August 31 at 11:40 AM
News IconOrexigen Therapeutics Enters Commercialization Agreement With Canadian Company (NASDAQ:OREX)
sdbj.com - August 31 at 11:40 AM
finance.yahoo.com logoOrexigen Stock Up on Commercialization Deal for Contrave (NASDAQ:OREX)
finance.yahoo.com - August 31 at 11:40 AM
investornewswire.com logoCan Shares Of Orexigen Therapeutics, Inc. (NASDAQ:OREX) Get To $5? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 30 at 9:58 AM
News IconStock Gapping Up Before the Bell: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Post News (NASDAQ:OREX)
www.kentuckypostnews.com - August 30 at 9:58 AM
schaeffersresearch.com logoBuzz Stocks: Apple Inc., Abercrombie & Fitch Co., and Orexigen Therapeutics, Inc. - Schaeffers Research (blog) (NASDAQ:OREX)
www.schaeffersresearch.com - August 30 at 9:58 AM
finance.yahoo.com logo8:01 am Orexigen Therapeutics announces that Valeant Canada (VRX (NASDAQ:OREX)
finance.yahoo.com - August 30 at 9:58 AM
publicnow.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release) (NASDAQ:OREX)
www.publicnow.com - August 30 at 9:58 AM
investornewswire.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) Gets 1 Recommendations To Sell - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 22 at 6:40 PM
investing.com logoOrexigen Therapeutics: In Control Of Its Own Destiny (NASDAQ:OREX)
www.investing.com - August 19 at 6:36 PM
investornewswire.com logoWill Orexigen Therapeutics, Inc. (NASDAQ:OREX) Hit $5 Price Target? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 16 at 9:56 AM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : August 15, 2016 (NASDAQ:OREX)
www.capitalcube.com - August 15 at 6:59 PM
finance.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Financials (NASDAQ:OREX)
finance.yahoo.com - August 13 at 6:20 PM
capitalcube.com logoOrexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:OREX)
www.capitalcube.com - August 12 at 6:48 PM
investornewswire.com logoWill Orexigen Therapeutics, Inc. (NASDAQ:OREX) Surprise This ... - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 8 at 6:55 PM
News IconOrexigen Reports Q2 Results (NASDAQ:OREX)
www.sdbj.com - August 7 at 6:20 PM
equities.com logoOrexigen Therapeutics Inc. (OREX) Jumps 6.84% on August 05 - Equities.com (NASDAQ:OREX)
www.equities.com - August 6 at 9:29 AM
News IconOrexigen Therapeutics Inc. (OREX) reports second-quarter earnings - BNB Daily (blog) (NASDAQ:OREX)
www.baseball-news-blog.com - August 6 at 9:29 AM
News IconOrexigen Reports Second Quarter Results (NASDAQ:OREX)
www.sdbj.com - August 5 at 6:52 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:OREX)
biz.yahoo.com - August 5 at 6:52 PM
finance.yahoo.com logoOrexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2 … (NASDAQ:OREX)
finance.yahoo.com - August 4 at 7:06 PM
sg.finance.yahoo.com logoOrexigen reports 2Q loss (NASDAQ:OREX)
sg.finance.yahoo.com - August 4 at 7:06 PM
News IconThe Pros and Cons of Clinical Trial Data Sharing (NASDAQ:OREX)
www.medscape.com - August 4 at 9:52 AM
biz.yahoo.com logoOrexigen Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:OREX)
biz.yahoo.com - August 4 at 9:52 AM
biz.yahoo.com logoQ2 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close (NASDAQ:OREX)
biz.yahoo.com - August 4 at 9:52 AM
News IconThe Potential Dark Side of Data Sharing (NASDAQ:OREX)
www.medscape.com - August 3 at 7:03 PM
reuters.com logoBRIEF-Orexigen Therapeutics unit, ROVI announce agreement - Reuters (NASDAQ:OREX)
www.reuters.com - August 2 at 11:38 AM
streetinsider.com logoOrexigen Therapeutics (OREX) Enters Mysimba Distribution Agreement with ROVI - StreetInsider.com (NASDAQ:OREX)
www.streetinsider.com - August 2 at 11:38 AM
streetinsider.com logoOrexigen Therapeutics (OREX) to Pay Takeda $15M in January as Part of Separation Agreement (NASDAQ:OREX)
www.streetinsider.com - August 1 at 11:20 AM
reuters.com logoBRIEF-Orexigen Therapeutics unit, ROVI announce agreement (NASDAQ:OREX)
www.reuters.com - August 1 at 11:20 AM
finance.yahoo.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos … (NASDAQ:OREX)
finance.yahoo.com - August 1 at 11:20 AM
twst.com logoOrexigen Therapeutics Inc.: Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization (NASDAQ:OREX)
www.twst.com - August 1 at 11:20 AM
prnewswire.com logoOrexigen Therapeutics Announces Commercialization and Distributorship ... (NASDAQ:OREX)
www.prnewswire.com - August 1 at 11:20 AM
publicnow.com logoOrexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization (NASDAQ:OREX)
www.publicnow.com - August 1 at 8:41 AM

Social

Orexigen Therapeutics (NASDAQ:OREX) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff